Evidence map›Paper›PMID 39061988›Full record

ReviewBiomedicines2024

Association between Proton Pump Inhibitor Use and Risk of Incident Chronic Kidney Disease: Systematic Review and Meta-Analysis.

Song Peng Ang, Jia Ee Chia, Carlos Valladares, Shreya Patel, Daniel Gewirtz, Jose Iglesias

Abstract readReview
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Gastrointestinal disease in end-stage renal disease.World journal of nephrology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Song Peng AngDepartment of Medicine, Rutgers Health Community Medical Center, Toms River, NJ 08755, USA.ORCID 0000-0001-8557-9880
Jia Ee ChiaDepartment of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA.
Carlos ValladaresDepartment of Medicine, Rutgers Health Community Medical Center, Toms River, NJ 08755, USA.
Shreya PatelTouro College of Osteopathic Medicine, New York, NY 10027, USA.ORCID 0009-0005-7114-1139
Daniel GewirtzDepartment of Medicine, Rutgers Health Community Medical Center, Toms River, NJ 08755, USA.
Jose IglesiasDepartment of Medicine, Rutgers Health Community Medical Center, Toms River, NJ 08755, USA.ORCID 0000-0001-7851-0498

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProton pump inhibitors (PPIs) are among the most commonly prescribed medications. Recently, PPI use has been linked to the development of chronic kidney disease (CKD) and cardiovascular events. Our study aimed to investigate the relationship between PPI use and the incidence of chronic kidney disease using a systematic review and meta-analysis.

methodsWe performed a comprehensive literature search in PubMed, Embase, and Cochrane databases from their inception until March 2024 for relevant studies. We compared outcomes between patients using PPIs, those not using PPIs, and those using histamine-2 receptor antagonists (H2RAs). Endpoints were pooled using the DerSimonian-and-Laird random-effects model as the hazard ratio (HR) with 95% confidence intervals (CIs).

resultsOur analysis included twelve studies with a total of 700,125 participants (286,488 on PPIs, 373,848 not on PPIs, and 39,789 on H2RAs), with follow-up periods ranging from three months to 14 years. The current meta-analysis revealed that PPI use is associated with a statistically significant increased risk of incident CKD (HR: 1.26, 95% CI: 1.16-1.38,

conclusionsOur multifaceted analysis showed that PPI use was associated with a higher incidence of CKD when compared to non-PPI use and H2RA use, respectively. These findings advocate for heightened vigilance and judicious use of long-term PPIs. Further large prospective longitudinal studies are warranted to validate these observations.

Indexed as

CKDESRDH2RAomeprazolepantoprazolePPI

Identifiers

PMID39061988
PMCPMC11274577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.